Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports.

A number of other equities research analysts have also recently issued reports on YMAB. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $9.77 on Wednesday. Y-mAbs Therapeutics has a one year low of $6.09 and a one year high of $20.90. The firm has a market cap of $437.60 million, a price-to-earnings ratio of -18.09 and a beta of 0.61. The stock’s 50-day moving average is $12.96 and its 200-day moving average is $12.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same period last year, the business earned ($0.18) EPS. On average, equities analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its position in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after acquiring an additional 56,244 shares during the period. Empire Financial Management Company LLC purchased a new position in shares of Y-mAbs Therapeutics in the third quarter valued at about $210,000. Geode Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after acquiring an additional 47,846 shares during the period. State Street Corp boosted its stake in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP boosted its stake in shares of Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.